The Use of Biomarkers in Early Diagnostics of Pancreatic Cancer

J 2018

The Use of Biomarkers in Early Diagnostics of Pancreatic Cancer

KUNOVSKÝ, Lumír, Pavla TESARIKOVA, Zdeněk KALA, Radek KROUPA, Petr KYSELA et. al.

Basic information

Original name

The Use of Biomarkers in Early Diagnostics of Pancreatic Cancer

Authors

KUNOVSKÝ, Lumír (203 Czech Republic, belonging to the institution), Pavla TESARIKOVA (203 Czech Republic), Zdeněk KALA (203 Czech Republic, belonging to the institution), Radek KROUPA (203 Czech Republic, belonging to the institution), Petr KYSELA (203 Czech Republic, belonging to the institution), Jiří DOLINA (203 Czech Republic, belonging to the institution) and Jan TRNA (203 Czech Republic, guarantor, belonging to the institution)

Edition

Canadian Journal of Gastroenterology and Hepatology, New York, Hindawi Publishing Corporation, 2018, 2291-2797

Other information

Language

English

Type of outcome

Článek v odborném periodiku

Field of Study

30219 Gastroenterology and hepatology

Country of publisher

United States of America

Confidentiality degree

není předmětem státního či obchodního tajemství

Impact factor

Impact factor: 1.714

RIV identification code

RIV/00216224:14110/18:00103475

Organization unit

Faculty of Medicine

UT WoS

000442877300001

Keywords in English

Pancreatic ductal adenocarcinoma

Abstract

V originále

Pancreatic ductal adenocarcinoma (PDAC) is one of the most lethal solid malignancies with increasing incidence. The poor prognosis is due to the aggressive nature of the tumor, late detection, and the resistance to chemotherapy and radiotherapy. A radical surgery procedure is the only treatment that has been shown to improve the 5-year survival rate to 20-25%. However, the majority of patients (80-85%) are diagnosed with locally advanced or metastatic disease and just 15-20% patients are diagnosed in an early stage allowing them to undergo the potentially curative surgical resection. The early detection of PDAC without the use of invasive methods is challenging and discovery of a cost-effective biomarker with high specificity and sensitivity could significantly improve the treatment and survival in these patients. In this review, we summarize current and newly examined biomarkers in early PDAC detection.

Citovat

KUNOVSKÝ, Lumír, Pavla TESARIKOVA, Zdeněk KALA, Radek KROUPA, Petr KYSELA, Jiří DOLINA and Jan TRNA. The Use of Biomarkers in Early Diagnostics of Pancreatic Cancer. Canadian Journal of Gastroenterology and Hepatology. New York: Hindawi Publishing Corporation, 2018, vol. 2018, No 5389820, p. 1-10. ISSN 2291-2797.

@article{1429160,
   author = {Kunovský, Lumír and Tesarikova, Pavla and Kala, Zdeněk and Kroupa, Radek and Kysela, Petr and Dolina, Jiří and Trna, Jan},
   article_location = {New York},
   article_number = {5389820},
   keywords = {Pancreatic ductal adenocarcinoma},
   language = {eng},
   issn = {2291-2797},
   journal = {Canadian Journal of Gastroenterology and Hepatology},
   title = {The Use of Biomarkers in Early Diagnostics of Pancreatic Cancer},
   volume = {2018},
   year = {2018}
}

TY  - JOUR
ID  - 1429160
AU  - Kunovský, Lumír - Tesarikova, Pavla - Kala, Zdeněk - Kroupa, Radek - Kysela, Petr - Dolina, Jiří - Trna, Jan
PY  - 2018
TI  - The Use of Biomarkers in Early Diagnostics of Pancreatic Cancer
JF  - Canadian Journal of Gastroenterology and Hepatology
VL  - 2018
IS  - 5389820
SP  - 1-10
EP  - 1-10
PB  - Hindawi Publishing Corporation
SN  - 22912797
KW  - Pancreatic ductal adenocarcinoma
N2  - Pancreatic ductal adenocarcinoma (PDAC) is one of the most lethal solid malignancies with increasing incidence. The poor prognosis is due to the aggressive nature of the tumor, late detection, and the resistance to chemotherapy and radiotherapy. A radical surgery procedure is the only treatment that has been shown to improve the 5-year survival rate to 20-25%. However, the majority of patients (80-85%) are diagnosed with locally advanced or metastatic disease and just 15-20% patients are diagnosed in an early stage allowing them to undergo the potentially curative surgical resection. The early detection of PDAC without the use of invasive methods is challenging and discovery of a cost-effective biomarker with high specificity and sensitivity could significantly improve the treatment and survival in these patients. In this review, we summarize current and newly examined biomarkers in early PDAC detection.
ER  -

KUNOVSKÝ, Lumír, Pavla TESARIKOVA, Zdeněk KALA, Radek KROUPA, Petr KYSELA, Jiří DOLINA and Jan TRNA. The Use of Biomarkers in Early Diagnostics of Pancreatic Cancer. \textit{Canadian Journal of Gastroenterology and Hepatology}. New York: Hindawi Publishing Corporation, 2018, vol.~2018, No~5389820, p.~1-10. ISSN~2291-2797.

Detailed Information on Publication Record